Global Novel Coronavirus (COVID-19) Vaccine Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 123

Published Date: 14 Jan 2024

Category: New Technology

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our latest research, the global Novel Coronavirus (COVID-19) Vaccine market size will reach USD million in 2030, growing at a CAGR of % over the analysis period.

The Novel Coronavirus (COVID-19) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Market segmentation
Novel Coronavirus (COVID-19) Vaccine market is split by Type and by Application. For the period 2024-2030, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
DNA
RNA
Others

Market segment by Application, can be divided into
Mild Symptom Patient
Critically Ill Patient

Market segment by players, this report covers
Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise

Market segment by regions, regional analysis covers
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)
South America
Middle East & Africa

The content of the study subjects, includes a total of 8 chapters:
Chapter 1, to describe Novel Coronavirus (COVID-19) Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Novel Coronavirus (COVID-19) Vaccine, with recent developments and future plans
Chapter 3, the Novel Coronavirus (COVID-19) Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4, to break the market size data at the region level, with key companies in the key region and Novel Coronavirus (COVID-19) Vaccine market forecast, by regions, with revenue, from 2024 to 2030.
Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2024 to 2030.
Chapter 7 and 8, to describe Novel Coronavirus (COVID-19) Vaccine research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Novel Coronavirus (COVID-19) Vaccine
    1.2 Classification of Novel Coronavirus (COVID-19) Vaccine by Type
        1.2.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type: 2024 Versus 2030
        1.2.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2030
        1.2.3 DNA
        1.2.4 RNA
        1.2.5 Others
    1.3 Global Novel Coronavirus (COVID-19) Vaccine Market by Application
        1.3.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application: 2024 Versus 2030
        1.3.2 Mild Symptom Patient
        1.3.3 Critically Ill Patient
    1.4 Global Novel Coronavirus (COVID-19) Vaccine Market Size & Forecast
    1.5 Market Drivers, Restraints and Trends
        1.5.1 Novel Coronavirus (COVID-19) Vaccine Market Drivers
        1.5.2 Novel Coronavirus (COVID-19) Vaccine Market Restraints
        1.5.3 Novel Coronavirus (COVID-19) Vaccine Trends Analysis

2 Company Profiles
    2.1 Inovio Pharmaceuticals
        2.1.1 Inovio Pharmaceuticals Details
        2.1.2 Inovio Pharmaceuticals Major Business
        2.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.1.4 Inovio Pharmaceuticals Recent Developments and Future Plans
    2.2 Takis Biotech (Evvivax)
        2.2.1 Takis Biotech (Evvivax) Details
        2.2.2 Takis Biotech (Evvivax) Major Business
        2.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.2.4 Takis Biotech (Evvivax) Recent Developments and Future Plans
    2.3 Zydus Cadila
        2.3.1 Zydus Cadila Details
        2.3.2 Zydus Cadila Major Business
        2.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.3.4 Zydus Cadila Recent Developments and Future Plans
    2.4 Codagenix, Inc.
        2.4.1 Codagenix, Inc. Details
        2.4.2 Codagenix, Inc. Major Business
        2.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.4.4 Codagenix, Inc. Recent Developments and Future Plans
    2.5 GeoVax, Inc.
        2.5.1 GeoVax, Inc. Details
        2.5.2 GeoVax, Inc. Major Business
        2.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.5.4 GeoVax, Inc. Recent Developments and Future Plans
    2.6 Bravovax
        2.6.1 Bravovax Details
        2.6.2 Bravovax Major Business
        2.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.6.4 Bravovax Recent Developments and Future Plans
    2.7 Janssen Pharmaceutical Companies
        2.7.1 Janssen Pharmaceutical Companies Details
        2.7.2 Janssen Pharmaceutical Companies Major Business
        2.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.7.4 Janssen Pharmaceutical Companies Recent Developments and Future Plans
    2.8 Altimmune
        2.8.1 Altimmune Details
        2.8.2 Altimmune Major Business
        2.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.8.4 Altimmune Recent Developments and Future Plans
    2.9 Vaxart
        2.9.1 Vaxart Details
        2.9.2 Vaxart Major Business
        2.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.9.4 Vaxart Recent Developments and Future Plans
    2.10 CanSino Biologics
        2.10.1 CanSino Biologics Details
        2.10.2 CanSino Biologics Major Business
        2.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.10.4 CanSino Biologics Recent Developments and Future Plans
    2.11 ExpreS2ion Biotechnologies ApS
        2.11.1 ExpreS2ion Biotechnologies ApS Details
        2.11.2 ExpreS2ion Biotechnologies ApS Major Business
        2.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.11.4 ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans
    2.12 Clover Biopharmaceuticals
        2.12.1 Clover Biopharmaceuticals Details
        2.12.2 Clover Biopharmaceuticals Major Business
        2.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.12.4 Clover Biopharmaceuticals Recent Developments and Future Plans
    2.13 GSK
        2.13.1 GSK Details
        2.13.2 GSK Major Business
        2.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.13.4 GSK Recent Developments and Future Plans
    2.14 Vaxil Bio Ltd.
        2.14.1 Vaxil Bio Ltd. Details
        2.14.2 Vaxil Bio Ltd. Major Business
        2.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.14.4 Vaxil Bio Ltd. Recent Developments and Future Plans
    2.15 Generex
        2.15.1 Generex Details
        2.15.2 Generex Major Business
        2.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.15.4 Generex Recent Developments and Future Plans
    2.16 Novavax, Inc.
        2.16.1 Novavax, Inc. Details
        2.16.2 Novavax, Inc. Major Business
        2.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.16.4 Novavax, Inc. Recent Developments and Future Plans
    2.17 Sanofi Pasteur
        2.17.1 Sanofi Pasteur Details
        2.17.2 Sanofi Pasteur Major Business
        2.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.17.4 Sanofi Pasteur Recent Developments and Future Plans
    2.18 Baylor
        2.18.1 Baylor Details
        2.18.2 Baylor Major Business
        2.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.18.4 Baylor Recent Developments and Future Plans
    2.19 iBio, Inc.
        2.19.1 iBio, Inc. Details
        2.19.2 iBio, Inc. Major Business
        2.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.19.4 iBio, Inc. Recent Developments and Future Plans
    2.20 Moderna, Inc.
        2.20.1 Moderna, Inc. Details
        2.20.2 Moderna, Inc. Major Business
        2.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.20.4 Moderna, Inc. Recent Developments and Future Plans
    2.21 Curevac
        2.21.1 Curevac Details
        2.21.2 Curevac Major Business
        2.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.21.4 Curevac Recent Developments and Future Plans
    2.22 ImmunoPrecise
        2.22.1 ImmunoPrecise Details
        2.22.2 ImmunoPrecise Major Business
        2.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Solutions
        2.22.4 ImmunoPrecise Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Share by Players (2024 & 2030)
    3.2 Novel Coronavirus (COVID-19) Vaccine Players Head Office, Products and Services Provided
    3.3 Novel Coronavirus (COVID-19) Vaccine Mergers & Acquisitions
    3.4 Novel Coronavirus (COVID-19) Vaccine New Entrants and Expansion Plans

4 Global Novel Coronavirus (COVID-19) Vaccine Forecast by Region
    4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region: 2024 VS 2030
    4.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region, (2024-2030)
    4.3 North America
        4.3.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in North America
        4.3.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in North America
        4.3.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2024-2030)
    4.4 Europe
        4.4.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in Europe
        4.4.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Europe
        4.4.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2024-2030)
    4.5 Asia-Pacific
        4.5.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific
        4.5.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific
        4.5.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2024-2030)
        4.5.4 China
        4.5.5 Japan
        4.5.6 South Korea
    4.6 South America
        4.6.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in South America
        4.6.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in South America
        4.6.3 South America Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2024-2030)
    4.7 Middle East & Africa
        4.7.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa
        4.7.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa
        4.7.3 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2024-2030)

5 Market Size Segment by Type
    5.1 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Type (2024-2030)
    5.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Type (2024-2030)

6 Market Size Segment by Application
    6.1 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Application (2024-2030)
    6.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Application (2024-2030)

7 Research Findings and Conclusion

8 Appendix
    8.1 Methodology
    8.2 Research Process and Data Source
    8.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Type, (USD Million), 2024 VS 2030
    Table 2. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Application, (USD Million), 2024 VS 2030
    Table 3. Inovio Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 4. Inovio Pharmaceuticals Major Business
    Table 5. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 6. Takis Biotech (Evvivax) Corporate Information, Head Office, and Major Competitors
    Table 7. Takis Biotech (Evvivax) Major Business
    Table 8. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 9. Zydus Cadila Corporate Information, Head Office, and Major Competitors
    Table 10. Zydus Cadila Major Business
    Table 11. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 12. Codagenix, Inc. Corporate Information, Head Office, and Major Competitors
    Table 13. Codagenix, Inc. Major Business
    Table 14. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 15. GeoVax, Inc. Corporate Information, Head Office, and Major Competitors
    Table 16. GeoVax, Inc. Major Business
    Table 17. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 18. Bravovax Corporate Information, Head Office, and Major Competitors
    Table 19. Bravovax Major Business
    Table 20. Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 21. Janssen Pharmaceutical Companies Corporate Information, Head Office, and Major Competitors
    Table 22. Janssen Pharmaceutical Companies Major Business
    Table 23. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 24. Altimmune Corporate Information, Head Office, and Major Competitors
    Table 25. Altimmune Major Business
    Table 26. Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 27. Vaxart Corporate Information, Head Office, and Major Competitors
    Table 28. Vaxart Major Business
    Table 29. Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 30. CanSino Biologics Corporate Information, Head Office, and Major Competitors
    Table 31. CanSino Biologics Major Business
    Table 32. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 33. ExpreS2ion Biotechnologies ApS Corporate Information, Head Office, and Major Competitors
    Table 34. ExpreS2ion Biotechnologies ApS Major Business
    Table 35. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 36. Clover Biopharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 37. Clover Biopharmaceuticals Major Business
    Table 38. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 39. GSK Corporate Information, Head Office, and Major Competitors
    Table 40. GSK Major Business
    Table 41. GSK Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 42. Vaxil Bio Ltd. Corporate Information, Head Office, and Major Competitors
    Table 43. Vaxil Bio Ltd. Major Business
    Table 44. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 45. Generex Corporate Information, Head Office, and Major Competitors
    Table 46. Generex Major Business
    Table 47. Generex Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 48. Novavax, Inc. Corporate Information, Head Office, and Major Competitors
    Table 49. Novavax, Inc. Major Business
    Table 50. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 51. Sanofi Pasteur Corporate Information, Head Office, and Major Competitors
    Table 52. Sanofi Pasteur Major Business
    Table 53. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 54. Baylor Corporate Information, Head Office, and Major Competitors
    Table 55. Baylor Major Business
    Table 56. Baylor Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 57. iBio, Inc. Corporate Information, Head Office, and Major Competitors
    Table 58. iBio, Inc. Major Business
    Table 59. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 60. Moderna, Inc. Corporate Information, Head Office, and Major Competitors
    Table 61. Moderna, Inc. Major Business
    Table 62. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 63. Curevac Corporate Information, Head Office, and Major Competitors
    Table 64. Curevac Major Business
    Table 65. Curevac Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 66. ImmunoPrecise Corporate Information, Head Office, and Major Competitors
    Table 67. ImmunoPrecise Major Business
    Table 68. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Solutions
    Table 69. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) by Players (2024 & 2030)
    Table 70. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Players (2024 & 2030)
    Table 71. Novel Coronavirus (COVID-19) Vaccine Players Head Office, Products and Services Provided
    Table 72. Novel Coronavirus (COVID-19) Vaccine Mergers & Acquisitions in the Past Five Years
    Table 73. Novel Coronavirus (COVID-19) Vaccine New Entrants and Expansion Plans
    Table 74. Global Market Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) Comparison by Region (2024 VS 2030)
    Table 75. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2024-2030)
    Table 76. Key Companies of Novel Coronavirus (COVID-19) Vaccine in North America
    Table 77. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in North America
    Table 78. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Europe
    Table 79. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Europe
    Table 80. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific
    Table 81. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific
    Table 82. Key Companies of Novel Coronavirus (COVID-19) Vaccine in China
    Table 83. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Japan
    Table 84. Key Companies of Novel Coronavirus (COVID-19) Vaccine in South Korea
    Table 85. Key Companies of Novel Coronavirus (COVID-19) Vaccine in South America
    Table 86. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in South America
    Table 87. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa
    Table 88. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa
    Table 89. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Type (2024-2030)
    Table 90. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Application (2024-2030)
List of Figures
    Figure 1. Novel Coronavirus (COVID-19) Vaccine Picture
    Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2030
    Figure 3. DNA
    Figure 4. RNA
    Figure 5. Others
    Figure 6. Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application in 2030
    Figure 7. Mild Symptom Patient Picture
    Figure 8. Critically Ill Patient Picture
    Figure 9. Global Novel Coronavirus (COVID-19) Vaccine Market Size, (USD Million): 2024 VS 2030
    Figure 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue and Forecast (2024-2030) & (USD Million)
    Figure 11. Novel Coronavirus (COVID-19) Vaccine Market Drivers
    Figure 12. Novel Coronavirus (COVID-19) Vaccine Market Restraints
    Figure 13. Novel Coronavirus (COVID-19) Vaccine Market Trends
    Figure 14. Inovio Pharmaceuticals Recent Developments and Future Plans
    Figure 15. Takis Biotech (Evvivax) Recent Developments and Future Plans
    Figure 16. Zydus Cadila Recent Developments and Future Plans
    Figure 17. Codagenix, Inc. Recent Developments and Future Plans
    Figure 18. GeoVax, Inc. Recent Developments and Future Plans
    Figure 19. Bravovax Recent Developments and Future Plans
    Figure 20. Janssen Pharmaceutical Companies Recent Developments and Future Plans
    Figure 21. Altimmune Recent Developments and Future Plans
    Figure 22. Vaxart Recent Developments and Future Plans
    Figure 23. CanSino Biologics Recent Developments and Future Plans
    Figure 24. ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans
    Figure 25. Clover Biopharmaceuticals Recent Developments and Future Plans
    Figure 26. GSK Recent Developments and Future Plans
    Figure 27. Vaxil Bio Ltd. Recent Developments and Future Plans
    Figure 28. Generex Recent Developments and Future Plans
    Figure 29. Novavax, Inc. Recent Developments and Future Plans
    Figure 30. Sanofi Pasteur Recent Developments and Future Plans
    Figure 31. Baylor Recent Developments and Future Plans
    Figure 32. iBio, Inc. Recent Developments and Future Plans
    Figure 33. Moderna, Inc. Recent Developments and Future Plans
    Figure 34. Curevac Recent Developments and Future Plans
    Figure 35. ImmunoPrecise Recent Developments and Future Plans
    Figure 36. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2024-2030)
    Figure 37. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region in 2030
    Figure 38. North America Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 39. Europe Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 40. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 41. South America Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 42. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2024-2030)
    Figure 43. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Type (2024-2030)
    Figure 44. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Application (2024-2030)
    Figure 45. Methodology
    Figure 46. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Inovio Pharmaceuticals
Takis Biotech (Evvivax)
Zydus Cadila
Codagenix, Inc.
GeoVax, Inc.
Bravovax
Janssen Pharmaceutical Companies
Altimmune
Vaxart
CanSino Biologics
ExpreS2ion Biotechnologies ApS
Clover Biopharmaceuticals
GSK
Vaxil Bio Ltd.
Generex
Novavax, Inc.
Sanofi Pasteur
Baylor
iBio, Inc.
Moderna, Inc.
Curevac
ImmunoPrecise

Related Reports

Global Novel Coronavirus (COVID-19) Vaccine Supply, Demand and Key Producers, 2023-2029

Global Novel Coronavirus (COVID-19) Vaccine Supply, Demand and Key Producers, 2023-2029

date 06 Sep 2023

date New Technology

The global Novel Coronavirus (COVID-19) Vaccine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Novel Coronavirus (COVID-19) Vaccine Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Novel Coronavirus (COVID-19) Vaccine Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 06 Sep 2023

date New Technology

According to our latest research, the global Novel Coronavirus (COVID-19) Vaccine market size will reach USD million in 2029, growing at a CAGR of % over the analysis period.

Product Tags

Novel Coronavirus (COVID-19) Vaccine

Ecobricks

Space Mining

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>